Cover Image
Market Research Report

Global Actinic Keratosis Drugs Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 582971
Published Content info 80 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Actinic Keratosis Drugs Market 2017-2021
Published: November 17, 2017 Content info: 80 Pages
Description

About Actinic Keratosis Drugs

Actinic keratosis is a pre-stage non-melanoma skin cancer caused by exposure to ultraviolet (UV) rays. Initially, the skin has a sandpaper-like texture with lesions. It can develop into squamous cell carcinoma, if not treated. The actinic keratosis drugs market includes nucleoside metabolic inhibitors, photosensitizers, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunomodulators.

Technavio's analysts forecast the global actinic keratosis drugs market to grow at a CAGR of 3.32% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global actinic keratosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Actinic Keratosis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Almirall
  • GALDERMA
  • LEO Pharma
  • Valeant

Other Prominent Vendors

  • Biofrontera
  • Novartis
  • Perrigo
  • Promius Pharma
  • Taro Pharmaceutical Industries
  • TOLMAR Pharmaceuticals
  • Vidac Pharma

Market driver

  • High prevalence of actinic keratosis
  • For a full, detailed list, view our report

Market challenge

  • Alternative treatment options
  • For a full, detailed list, view our report

Market trend

  • Novel drug delivery mechanisms
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR15304

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: DISEASE OVERVIEW

  • Actinic keratosis

PART 06: MARKET LANDSCAPE

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY DRUG CLASS

  • Nucleoside metabolic inhibitors
  • Immunomodulators
  • Photosensitizers
  • NSAIDs

PART 09: REGIONAL LANDSCAPE

  • Regional comparison
  • Actinic keratosis drugs market in Americas
  • Actinic keratosis drugs market in EMEA
  • Actinic keratosis drugs market in APAC
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Novel drug delivery mechanisms
  • Advanced diagnostic techniques
  • Drug development by 3D tissue modelling
  • Industry focus on actinic keratosis R&D activity
  • Development of targeted drugs having selectivity to cells

PART 13: VENDOR LANDSCAPE

  • Almirall
  • GALDERMA
  • LEO Pharma
  • Valeant
  • Other prominent vendors

PART 14: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global actinic keratosis drugs market
  • Exhibit 02: Global actinic keratosis drugs market 2016-2021 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Pipeline landscape by development phase
  • Exhibit 05: Key clinical trials
  • Exhibit 06: Global actinic keratosis drugs market by drug class 2016
  • Exhibit 07: Global actinic keratosis drugs market by drug class 2021
  • Exhibit 08: Global actinic keratosis drugs market by nucleoside metabolic inhibitors 2016-2021 ($ millions)
  • Exhibit 09: Global actinic keratosis drugs market by immunomodulators 2016-2021 ($ millions)
  • Exhibit 10: Global actinic keratosis drugs market by photosensitizers 2016-2021 ($ millions)
  • Exhibit 11: Global actinic keratosis drugs market by NSAIDs 2016-2021 ($ millions)
  • Exhibit 12: Global actinic keratosis drugs market by geography 2016-2021 (% share)
  • Exhibit 13: Regional comparison
  • Exhibit 14: Actinic keratosis drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 15: Actinic keratosis drugs market in Americas - Year over year growth 2017-2021
  • Exhibit 16: Actinic keratosis drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 17: Actinic keratosis drugs market in EMEA - Year over year growth 2017-2021
  • Exhibit 18: Actinic keratosis drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 19: Actinic keratosis drugs market in APAC - Year over year growth 2017-2021
  • Exhibit 20: Key leading countries
  • Exhibit 21: Almirall: Key highlights
  • Exhibit 22: Almirall: Strength assessment
  • Exhibit 23: Almirall: Strategy assessment
  • Exhibit 24: Almirall: Opportunity assessment
  • Exhibit 25: GALDERMA: Key highlights
  • Exhibit 26: GALDERMA: Strength assessment
  • Exhibit 27: GALDERMA: Strategy assessment
  • Exhibit 28: GALDERMA: Opportunity assessment
  • Exhibit 29: LEO Pharma: Key highlights
  • Exhibit 30: LEO Pharma: Strength assessment
  • Exhibit 31: LEO Pharma: Strategy assessment
  • Exhibit 32: LEO Pharma: Opportunity assessment
  • Exhibit 33: Valeant: Key highlights
  • Exhibit 34: Valeant: Strength assessment
  • Exhibit 35: Valeant: Strategy assessment
  • Exhibit 36: Valeant: Opportunity assessment
Back to Top